Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
Stroke. 2009;40:e380-e389
Published online before print March 12, 2009, doi: 10.1161/STROKEAHA.108.528752
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
40/5/e380    most recent
STROKEAHA.108.528752v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Whiteley, W.
Right arrow Articles by Sandercock, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Whiteley, W.
Right arrow Articles by Sandercock, P.
Right arrowPubmed/NCBI databases
Medline Plus Health Information
*Stroke
Related Collections
Right arrow Other diagnostic testing
Right arrow Carotid and Vertebral A. Dissection
Right arrow Other Research

(Stroke. 2009;40:e380.)
© 2009 American Heart Association, Inc.


Progress Review

Blood Markers for the Prognosis of Ischemic Stroke

A Systematic Review

William Whiteley, BM BCh, MRCP; Wei Li Chong, BM BCh; Anshuman Sengupta, BM BCh Peter Sandercock, MD, FRCP

From the Division of Clinical Neurosciences, University of Edinburgh, Edinburgh, UK.

Correspondence to William Whiteley, BMBCh, MRCP, Department of Clinical Neurosciences, Western General Hospital, Edinburgh EH4 2XU, UK. E-mail william.whiteley{at}ed.ac.uk

Background and Purpose— The performance of validated prognostic clinical models in acute ischemic stroke might be improved by addition of data on blood biomarkers.

Methods— We searched Medline and EMBASE from 1966 to January 2007 for studies of blood markers in patients with ischemic stroke and an assessment of outcome (death, disability, or handicap). We adopted several strategies to reduce bias.

Results— Studies were generally small (median number of subjects, 85; interquartile range, 49 to 184). Few had evidence of a sample size calculation (7 of 82 [9%]) or reported blinding to whether patients had stroke (21 of 82 [26%]). Of the 66 studies reporting a measure of association, 10 did not adjust for age or stroke severity, 14 adjusted for age, 7 adjusted for severity, and 35 adjusted for both; 30% (20 of 66) used a data-dependent threshold to predict good or bad outcome. There was evidence of within-study reporting bias and publication bias. Cardiac markers showed the most consistent association with poor outcome.

Conclusions— Blood biomarkers might provide useful information to improve the prediction of outcome after acute ischemic stroke. However, this review showed that many studies were subject to bias. Although some markers had some predictive ability, none of the studies was able to demonstrate that the biomarker added predictive power to a validated clinical model. The clinical usefulness of blood biomarkers for predicting prognosis in the setting of ischemic stroke has yet to be established.

Supplemental Appendix I: Studies Included in the Systematic Review

Supplemental Appendix II: Electronic Search Strategy

Supplemental Appendix III: Quality Questionnaire